Purpose
|
Axitinib is an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3. Axitinib is marketed under the name Inlyta®, and if one previous systemic therapy for kidney cell cancer has failed, axitinib is indicated.
|
Characteristics
|
Tradename: AG 013736 Source of Compound: synthetic Target: c-Kit inhibitor, PDGFR inhibitor, VEGFR inhibitor Receptor: c-Kit,PDGFRβ,VEGFR1, VEGFR2, VEGFR3 Status: USP,CP,
|
Purification
|
All the products are sent with COA, HPLC and NMR inspection report to guarantee the quality.
|
Purity
|
99 %
|
Formula
|
C22H18N4OS
|
Solubility
|
Soluble in DMSO
|